Company Seeks FDA Emergency Approval for COVID-19 Antibody TherapyLast Updated: October 07, 2020. Eli Lilly and Co. is seeking U.S. approval for emergency use of an experimental antibody therapy for COVID-19.
WEDNESDAY, Oct. 7, 2020 (HealthDay News) -- Eli Lilly and Co. is seeking U.S. approval for emergency use of an experimental antibody therapy for COVID-19.
The request to the U.S. Food and Drug Administration is based on partial clinical trial findings suggesting the drug reduced symptoms, the amount of virus, hospitalizations, and emergency department visits for patients with mild or moderate COVID-19, the Associated Press reported.
The results were released Wednesday in a news release, and they have not been published or reviewed by independent researchers.
The FDA granted emergency approval for the antiviral drug remdesivir, but it is not clear if there is enough evidence for Lilly's antibody therapy to be approved, the AP reported.
|Previous: U.S., French Researchers Awarded Nobel Prize in Chemistry||Next: 28 Percent With T1DM Received Remote Care in Pandemic|
Reader comments on this article are listed below. Review our comments policy.